GammaCan International to Present at the 6th Annual Biotech in Europe Investor Forum
September 28 2006 - 6:30AM
Business Wire
GammaCan International, Inc. (OTC BB: GCAN) a developer of
immunotherapies for the treatment cancer and other diseases, today
announced that Patrick Schnegelsberg, Chief Executive Officer, is
scheduled to present GammaCan's second generation product under
development for the treatment of melanoma � VitiGam, to the
investor community at the Sachs Associates� Biotech Investor Forum
in Europe. The conference will be held at the Swiss�tel
Z�rich-Oerlikon in Switzerland from October 4-5, 2006. Mr.
Schnegelsberg is scheduled to present on Wednesday, October 4th at
12:20 GMT. About VitiGam: VitiGam is GammaCan's second generation
intravenous IgG-based product and a first-in-class anti-cancer
immunotherapy. GammaCan plans on having VitiGam to enter phase I/II
testing under a US IND in the near future after it recently held a
pre-IND meeting with the FDA. VitiGam is being designed to target
metastatic melanoma patients with Stage III and IV melanoma.
VitiGam is an IgG product that is different from standard IgGs: It
is manufactured from the plasma of donors with vitiligo, a benign
autoimmune skin condition affecting up to 2% of the general
population. GammaCan scientists have shown that this "enriched"
vitiligo IgG (VitiGam) contains potent anti-melanoma activity in
both in vitro and mouse xenograft melanoma models. Thus, GammaCan
expects VitiGam to provide (1) anti-melanoma activity directed
specifically against malignant melanoma cells and (2) non-specific
anti-cancer activity - as is the case with IgG in general. About
GammaCan GammaCan is focusing on the commercialization of an
innovative anti-cancer immunotherapy to treat metastatic cancer.
GammaCan's platform is based on IgG, a safe, relatively non-toxic
human plasma-based product, currently used to treat a variety of
immune deficiencies and autoimmune diseases. IgG works by
strengthening the patient's immune system. Many experts currently
view immunotherapy as a future alternative to today's standard
chemotherapy. GammaCan is developing VitiGam, its second generation
program. VitiGam is an IgG derived from the plasma of vitiligo
donors and is being developed to treat malignant melanoma. GammaCan
owns, and has applied for US patent protection covering the use of
IgG and vitiligo-derived IgG (VitiGam). For more information about
GammaCan visit www.GammaCan.com or call the company's headquarters
in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free
1-866-308-0396 (from North America). Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this
release include statements regarding the commercialization of an
anti-cancer immunotherapy and the Company developing the boosting
of cancer patients' immune systems with IgG into an effective
treatment. Actual outcomes and the Company's actual results could
differ materially from those in such forward-looking statements.
Factors that could cause actual results to differ materially
include risks and uncertainties such as the inability to finance
the planned development of the technology, unforeseen technical
difficulties in developing the technology, the inability to obtain
regulatory approval for human use, competitors' therapies proving
more effective, cheaper or otherwise preferable for consumers,
inability to market the product we produce, among other factors,
all of which could among other things, delay or prevent product
release or cause our company to fail. For further risk factors see
the risk factors associated with other early state medical research
and development companies filed with the SEC on Edgar. GammaCan
International, Inc. (OTC BB: GCAN) a developer of immunotherapies
for the treatment cancer and other diseases, today announced that
Patrick Schnegelsberg, Chief Executive Officer, is scheduled to
present GammaCan's second generation product under development for
the treatment of melanoma - VitiGam, to the investor community at
the Sachs Associates' Biotech Investor Forum in Europe. The
conference will be held at the Swissotel Zurich-Oerlikon in
Switzerland from October 4-5, 2006. Mr. Schnegelsberg is scheduled
to present on Wednesday, October 4th at 12:20 GMT. About VitiGam:
VitiGam is GammaCan's second generation intravenous IgG-based
product and a first-in-class anti-cancer immunotherapy. GammaCan
plans on having VitiGam to enter phase I/II testing under a US IND
in the near future after it recently held a pre-IND meeting with
the FDA. VitiGam is being designed to target metastatic melanoma
patients with Stage III and IV melanoma. VitiGam is an IgG product
that is different from standard IgGs: It is manufactured from the
plasma of donors with vitiligo, a benign autoimmune skin condition
affecting up to 2% of the general population. GammaCan scientists
have shown that this "enriched" vitiligo IgG (VitiGam) contains
potent anti-melanoma activity in both in vitro and mouse xenograft
melanoma models. Thus, GammaCan expects VitiGam to provide (1)
anti-melanoma activity directed specifically against malignant
melanoma cells and (2) non-specific anti-cancer activity - as is
the case with IgG in general. About GammaCan GammaCan is focusing
on the commercialization of an innovative anti-cancer immunotherapy
to treat metastatic cancer. GammaCan's platform is based on IgG, a
safe, relatively non-toxic human plasma-based product, currently
used to treat a variety of immune deficiencies and autoimmune
diseases. IgG works by strengthening the patient's immune system.
Many experts currently view immunotherapy as a future alternative
to today's standard chemotherapy. GammaCan is developing VitiGam,
its second generation program. VitiGam is an IgG derived from the
plasma of vitiligo donors and is being developed to treat malignant
melanoma. GammaCan owns, and has applied for US patent protection
covering the use of IgG and vitiligo-derived IgG (VitiGam). For
more information about GammaCan visit www.GammaCan.com or call the
company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America). Safe Harbor
Statement: Statements in this document that are not purely
historical are forward-looking statements. Forward-looking
statements in this release include statements regarding the
commercialization of an anti-cancer immunotherapy and the Company
developing the boosting of cancer patients' immune systems with IgG
into an effective treatment. Actual outcomes and the Company's
actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology,
unforeseen technical difficulties in developing the technology, the
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable
for consumers, inability to market the product we produce, among
other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further
risk factors see the risk factors associated with other early state
medical research and development companies filed with the SEC on
Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024